 | • レポートコード：MRC2203A366 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のCRISPR技術市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（酵素、キット・試薬、ガイドRNA、その他）分析、用途別（生体医療、農業、工業、その他）分析、エンドユーザー別（製薬企業・バイオテクノロジー企業、学術・政府研究機関、その他（CRO））分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のCRISPR技術市場規模：製品別（酵素、キット・試薬、ガイドRNA、その他） ・世界のCRISPR技術市場規模：用途別（生体医療、農業、工業、その他） ・世界のCRISPR技術市場規模：エンドユーザー別（製薬企業・バイオテクノロジー企業、学術・政府研究機関、その他（CRO）） ・世界のCRISPR技術市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Agilent Technologies、Cellecta, Inc.、GeneCopoeia, Inc.、…） ・市場機会・将来傾向 |
Global CRISPR Technology market is expected to witness a CAGR of 24.3% during the forecast period. Certain factors that are driving the market growth include increasing government and private funding, rising demand and adoption of crispr, technological advancements.
The rise in funding, initiatives by the government to develop vaccines, medical technologies, drugs, devices are further propelling the growth of the genome editing market globally. For instance, In May 2018, Feng Zhang’s company Beam Therapeutics, new startup to develop CRISPR, officially came out with USD 87 million in series. A funding and a mission to develop “precision genetic medicines” that use CRISPR technology to edit just one nucleotide base, or “letter,” in the genome at a time. In 2018, Inscripta Colorado-based biotech acquired Solana Biosciences to ramp up the commercialisation of its gene-editing technology. Aiming to broaden access to CRISPR by offering new enzymes for free, and to boost CRISPR research by outfitting scientists with a full suite of tools. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering.
Key Market Trends
Biomedical is Expected to Hold Significant Market Share in the Application Segment
At present, the CRISPR (clustered regularly interspaced short palindromic repeat) restoration system is undeniably considered as one of the most suitable as well as promising options for genome editing. As compared to previous systems, CRISPR has more potentials and applications. Among all these, one important application is the use of CRISPR in understanding various genetic and epigenetic diseases including cancer. Study of cancer by the CRISPR system is mostly done by two approaches i.e. turning on the tumour suppressor genes and turning off the oncogenes. As per the exact capability of CRISPR, this system can also be utilized to create specific mutations in different cell lines in order to model the cancers. This type of modeling can result in a better understanding of a variety of diseases such as cancer and the ability to further develop effective drugs.
North America Dominates the Market and Expected to do Same in the Forecast Period
The region, especially the United States, has always been a pioneer in the field of genome editing, mostly due to the favorable government initiatives and increase in funding. The first ever US trial of CRISPR in humans has begun in April 2019. Two patients are presently being treated as part of a study being conducted by University of Pennsylvania. According to NPR (National Public Radio, America), both have certain forms of cancer which are difficult to treat and both have relapsed after standard treatments. As part of the trial, researchers are taking immune cells from the patients’ bodies and then are editing them with CRISPR before again putting them back in. Such novel researches are expected to drive the overall market growth throughout the region.
Competitive Landscape
The global CRISPR Technologymarket is highly competitive and consists of a number of major players. Companies like Agilent Technologies, Cellecta, Inc., GeneCopoeia, Inc., GenScript, Horizon Discovery Group, Integrated DNA Technologies (IDT), Merck KGaA, New England Biolabs, Origene Technologies, Inc., Thermo Fisher Scientific, among others, hold the substantial market share in the CRISPR Technology market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Government and Private Funding
4.2.2 Rising Demand and Adoption of CRISPR
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Costs of Using CRISPR
4.3.2 Ethical Concerns Related to Genetic Research
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Product
5.1.1 Enzymes
5.1.2 Kits & Reagents
5.1.3 Guide RNA
5.1.4 Others
5.2 Application
5.2.1 Biomedical
5.2.2 Agricultural
5.2.3 Industrial
5.2.4 Others
5.3 End User
5.3.1 Pharmaceutical companies and Biotechnology Companies
5.3.2 Academics and Government Research Institutes
5.3.3 Others (CROs etc.)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Cellecta, Inc.
6.1.3 GeneCopoeia, Inc.
6.1.4 GenScript
6.1.5 Horizon Discovery Group
6.1.6 Integrated DNA Technologies (IDT)�
6.1.7 Merck KGaA
6.1.8 New England Biolabs
6.1.9 Origene Technologies, Inc.
6.1.10 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS